A multicentre controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage.
In a combined clinical trial with gold in patients with rheumatoid arthritis (RA) 95 patients were treated with a high initial dosage of 2,500 mg aurothioglucose in 21 weeks. Afterwards 48 of these patients received a maintenance dosage of gold and 47 patients placebo injections. Another group of 101 patients received 1,000 mg gold in 21 weeks. Finally a maintenance dose of gold was administered to 49 of these patients, to the other 52 patients placebo injections were administered. For the treatment of RA a high dosage of a gold compound offers no advantage over a low dosage. After a high dosage one can expect a significantly higher number of side effects. The development of toxicity does not influence the ultimate results. A second course of gold has hardly any benificial effect. Prolonged administration of gold is usually well-tolerated; whether it has substantial and sustained therapeutic value remains dubious. Progression of radiological abnormalities can be observed at the same moment that signs and other symptoms of the disease show improvement.
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000139:chemically induced; D000844:Ankylosis / Q000000981:diagnostic imaging; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006051:Aurothioglucose / Q000627:therapeutic use; D001799:Blood Sedimentation; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D005500:Follow-Up Studies; D006046:Gold / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D011859:Radiography
D006051:Aurothioglucose; D006046:Gold